Medifast Inc MED
We take great care to ensure that the data presented and summarized in this overview for MEDIFAST INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MED
View all-
Jim Simons Renaissance Technologies LLC | New York, Ny889KShares$12.3 Million0.02% of portfolio
-
Black Rock Inc. New York, NY829KShares$11.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA774KShares$10.7 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA386KShares$5.32 Million0.01% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY333KShares$4.6 Million0.0% of portfolio
-
Morgan Stanley New York, NY294KShares$4.05 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC289KShares$3.98 Million0.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA266KShares$3.66 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA256KShares$3.54 Million0.0% of portfolio
-
American Century Companies Inc Kansas City, MO225KShares$3.1 Million0.0% of portfolio
Latest Institutional Activity in MED
Top Purchases
Top Sells
About MED
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland.
Insider Transactions at MED
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 25
2025
|
Scott Schlackman Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,168
+30.42%
|
-
|
|
Jun 25
2025
|
Jeffrey J Brown Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,616
+23.69%
|
$123,696
$6.7 P/Share
|
|
Jun 25
2025
|
Elizabeth A. Geary Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,168
+36.36%
|
-
|
|
Jun 25
2025
|
Michael A. Hoer Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,168
+29.94%
|
-
|
|
Jun 25
2025
|
Andrea B Thomas Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,168
+31.74%
|
-
|
|
Jun 13
2025
|
Daniel R Chard Chairman & CEO |
BUY
Open market or private purchase
|
Indirect |
381
+0.25%
|
$4,953
$13.13 P/Share
|
|
Mar 25
2025
|
Daniel R Chard Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
124,953
+41.49%
|
-
|
|
Mar 25
2025
|
Jonathan Barrett Mac Kenzie VP, Finance & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
7,671
+40.78%
|
-
|
|
Mar 25
2025
|
James P. Maloney Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,161
+36.35%
|
-
|
|
Mar 17
2025
|
Daniel R Chard Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,864
-3.51%
|
$26,096
$14.35 P/Share
|
|
Mar 17
2025
|
James P. Maloney Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
438
-2.36%
|
$6,132
$14.35 P/Share
|
|
Mar 17
2025
|
Jonathan Barrett Mac Kenzie VP, Finance & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
99
-2.78%
|
$1,386
$14.35 P/Share
|
|
Mar 16
2025
|
Daniel R Chard Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
944
-1.74%
|
$12,272
$13.94 P/Share
|
|
Mar 16
2025
|
James P. Maloney Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
123
-0.66%
|
$1,599
$13.94 P/Share
|
|
Mar 16
2025
|
Jonathan Barrett Mac Kenzie VP, Finance & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
60
-1.65%
|
$780
$13.94 P/Share
|
|
Mar 13
2025
|
Daniel R Chard Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,001
-8.46%
|
$65,013
$13.87 P/Share
|
|
Mar 13
2025
|
James P. Maloney Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
835
-4.27%
|
$10,855
$13.87 P/Share
|
|
Mar 13
2025
|
Jonathan Barrett Mac Kenzie VP, Finance & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
280
-7.17%
|
$3,640
$13.87 P/Share
|
|
Sep 13
2024
|
Jonathan Barrett Mac Kenzie VP, Finance & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
11
-0.28%
|
$198
$18.9 P/Share
|
|
Jun 20
2024
|
Andrea B Thomas Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,596
+33.92%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 222K shares |
|---|---|
| Open market or private purchase | 381 shares |
| Payment of exercise price or tax liability | 9.66K shares |
|---|